nature.com
Tissue transcriptional programs stratify Crohn's disease by therapeutic response and clinical ...
The study identifies colonic gene-expression programs that correlate with treatment failure, higher surgery rates, and perianal disease in Crohn’s — findings that could guide future prognostic tests and targeted therapies.
Clinicians and researchers working on Crohn’s disease biomarkers and treatment stratification; adult patients interested in the molecular basis of disease heterogeneity.
What To Know
What to know This study analyzed whole-transcriptome RNA sequencing from non-inflamed colonic biopsies of 101 people with Crohn’s disease and identified 15 transcriptional programs that define molecular subtypes of disease.
Several programs were linked to clinical outcomes: a neutrophil activation signature associated with primary and secondary treatment failure, a fibro-proliferative program tied to higher surgical burden, an antimicrobial (DEFA5/DEFA6) program enriched in patients with treatment failure, and a distinct program associated with perianal disease.
Why this matters The work suggests that mucosal gene-expression profiles can identify biologically meaningful Crohn’s disease states that predict treatment resistance, surgical risk, and perianal involvement. That could help researchers and clinicians develop prognostic biomarkers and targeted treatment strategies in the future.
Study details and scope The findings come from RNA-sequencing and co-expression network analysis of colonic biopsy tissue from a well-characterized cohort; some signatures were validated by immunofluorescence. This is a discovery and association study that links molecular programs to outcomes rather than testing a specific treatment intervention.
Next steps for patients and clinicians These results support further biomarker development and validation in independent cohorts before any clinical test or treatment-change is recommended. For now, this informs research directions more than immediate clinical care.
This is a tissue-based transcriptomic association study (RNA-seq and co-expression analysis) in a single cohort with some validation; it suggests candidate biomarkers but does not yet establish clinical tests or change treatment recommendations.
